AzurRx BioPharma, Inc. announced that it has initiated its Phase II RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide for the treatment of COVID-19 related gastrointestinal infections.
[AzurRx BioPharma, Inc.]
6445212 nan items 1 apa default asc 1
Scientists evaluated the safety and describe the clinical changes after IV administration of allogeneic human umbilical cord MSCs, in patients with bilateral pneumonia caused by COVID-19, complicated with severe acute respiratory distress syndrome, as compassionate treatment.
[Aging and Disease]
-BeiGene, Ltd. announced that the Phase II trial evaluating BRUKINSA® in patients hospitalized with respiratory symptoms of COVID-19, requiring supplemental oxygen without mechanical ventilation, did not meet the co-primary efficacy endpoints of respiratory failure-free survival or reduction in days on oxygen as compared to placebo.
[BeiGene, Ltd. (BusinessWire, Inc.)]
6445218 nan items 1 apa default asc 1
Scientists unexpectedly found that the complement system was one of the intracellular pathways most highly induced by SARS-CoV-2 infection in lung epithelial cells.
6445218 AMX6S9CV items 1 apa default asc 1
Yan, B., Freiwald, T., Chauss, D., Wang, L., West, E., Mirabelli, C., Zhang, C. J., Nichols, E.-M., Malik, N., Gregory, R., Bantscheff, M., Ghidelli-Disse, S., Kolev, M., Frum, T., Spence, J. R., Sexton, J. Z., Alysandratos, K. D., Kotton, D. N., Pittaluga, S., … Kazemian, M. (2021). SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Science Immunology, 6(58). https://doi.org/10.1126/sciimmunol.abg0833 Cite
The authors summarize what is now known about adaptive immunity to SARS-CoV-2 and draw comparisons with immunity to other respiratory viruses, focusing on the longevity of protective responses.
[Trends in Microbiology]
Scientists report that mutations frequently found in the S proteins of SARS-CoV-2 from mink were mostly compatible with efficient entry into human cells and its inhibition by soluble ACE2.
6445218 28AZBEEK items 1 apa default asc 1
Hoffmann, M., Zhang, L., Krüger, N., Graichen, L., Kleine-Weber, H., Hofmann-Winkler, H., Kempf, A., Nessler, S., Riggert, J., Winkler, M. S., Schulz, S., Jäck, H.-M., & Pöhlmann, S. (2021). SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Reports, 0(0). https://doi.org/10.1016/j.celrep.2021.109017 Cite
Researchers report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with COVID-19.
[Science Translational Medicine]
6445218 8JKTLFXK items 1 apa default asc 1
Jones, B. E., Brown-Augsburger, P. L., Corbett, K. S., Westendorf, K., Davies, J., Cujec, T. P., Wiethoff, C. M., Blackbourne, J. L., Heinz, B. A., Foster, D., Higgs, R. E., Balasubramaniam, D., Wang, L., Zhang, Y., Yang, E. S., Bidshahri, R., Kraft, L., Hwang, Y., Žentelis, S., … Falconer, E. (2021). The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abf1906 Cite
Scientists showed a range of T cell assays that differentially captured immune function to characterise SARS-CoV-2 responses.
6445218 3QKY4FNL items 1 apa default asc 1
Ogbe, A., Kronsteiner, B., Skelly, D. T., Pace, M., Brown, A., Adland, E., Adair, K., Akhter, H. D., Ali, M., Ali, S.-E., Angyal, A., Ansari, M. A., Arancibia-Cárcamo, C. V., Brown, H., Chinnakannan, S., Conlon, C., de Lara, C., de Silva, T., Dold, C., … Dunachie, S. (2021). T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 12(1), 2055. https://doi.org/10.1038/s41467-021-21856-3 Cite
Scientists propose that SARS-CoV-2 infection induces a process known as immunothrombosis, in which activated neutrophils and monocytes interact with platelets and the coagulation cascade, leading to intravascular clot formation in small and larger vessels.
[Nature Reviews Immunology]
6445218 TNI63CHL items 1 apa default asc 1
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., & Abbate, A. (2021). Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nature Reviews Immunology, 1–11. https://doi.org/10.1038/s41577-021-00536-9 Cite
Scientists demonstrated that hypoxia and the hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor Roxadustat reduced angiotensin-converting enzyme expression and inhibited SARS-CoV-2 entry and replication in lung epithelial cells via a HIF-1α dependent pathway.
1254621 MAI5I84R items 1 apa default asc 1
Wing, P. A., Keeley, T. P., Zhuang, X., Lee, J. Y., Prange-Barczynska, M., Tsukuda, S., Morgan, S. B., Harding, A. C., Argles, I. L. A., Kurlekar, S., Noerenberg, M., Thompson, C. P., Huang, K.-Y. A., Balfe, P., Watashi, K., Castello, A., Hinks, T. S., James, W., Ratcliffe, P. J., … McKeating, J. A. (2021). Hypoxic and pharmacological activation of HIFs inhibits SARS-CoV-2 infection of lung epithelial cells. Cell Reports, 0(0). https://doi.org/10.1016/j.celrep.2021.109020 Cite
Foresee Pharmaceuticals Co., Ltd. announced the initiation of patient dosing in the Phase II/III clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated Acute Respiratory Distress Syndrome.
[Foresee Pharmaceuticals Co., Ltd.]
1254621 nan items 1 apa default asc 1